Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
Sponsor: Virogin Biotech Ltd.
Summary
VG2025 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection. Currently, one phase I dose escalation safety study has been completed in China and the United States respectively, both demonstrating excellent safety profiles with no dose-limiting toxicities (DLTs) observed and no maximum tolerated dose (MTD) identified. Moreover, it has shown preliminary efficacy in treating advanced tumors. Considering the actual clinical needs and the volume of intratumoral administration, a more appropriate recommended phase 2 dose (RP2D) level has been selected for the phase II clinical trial.
Official title: An Open-label Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of VG2025 in the Treatment of Advanced Intrahepatic Cholangiocarcinoma
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-08-25
Completion Date
2028-11-13
Last Updated
2026-09-22
Healthy Volunteers
No
Conditions
Interventions
VG2025
Recommended Phase II Dose, Intratumoral Injection, Q4W
Locations (1)
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, China